secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093942
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics Q2 net loss $12.4M; RIVER trial ~80% enrolled, topline Q4 2024
--------------------------------------------------------------------------------

- Q2 2024 net loss of $12.4M vs $7.1M in Q2 2023; R&D expenses $10.0M, up from $5.8M.
- Cash and equivalents $69.5M; cash runway expected into 2026.
- Phase 2a RIVER trial (RCC) ~80% enrolled; topline data expected Q4 2024.
- Phase 2b CORAL trial (IPF cough) sample size re-estimation expected Q4 2024; topline H1 2025.
- Appointed Margaret Garin, MD, MSCR as VP of Clinical Development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024093942/0000950170-24-093942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024093942/trvi-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer